[ad_1] STOCKHOLM, Nov. 14, 2025 /PRNewswire/ — The independent Data Safety Monitoring Board (DSMB) has completed its sixth scheduled safety review of Diamyd Medical’s registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy Diamyd®. […]
Tag: Diamyd Medical AB
Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process
[ad_1] STOCKHOLM, Dec. 13, 2024 /PRNewswire/ — Diamyd Medical today announced a positive in-person Type C meeting with the U.S. Food and Drug Administration (FDA), where alignment was achieved on key components of the planned […]
In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress
[ad_1] STOCKHOLM, Nov. 6, 2024 /PRNewswire/ — (IDS) Congress in Bruges, Belgium. The analysis will be presented at a Satellite Symposium organized by Abbott. The results support the robustness of the treatment effects and underscore […]
In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress
[ad_1] STOCKHOLM, Nov. 6, 2024 /PRNewswire/ — (IDS) Congress in Bruges, Belgium. The analysis will be presented at a Satellite Symposium organized by Abbott. The results support the robustness of the treatment effects and underscore […]
